Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Esupaglutide alpha - Innogen Pharmaceutical Technology

Next Previous
Drug Profile

Esupaglutide alpha - Innogen Pharmaceutical Technology

Alternative Names: Diabegone; Efsubaglutide alfa; Efsubaglutide alfa - Innogen Pharmaceutical Technology; Enolight; Esupaglutide α; Innolight; Supaglutide - Innogen Pharmaceutical Technology; Supaglutide injection - Shanghai Innogen Pharmaceutical Technology; Yinuoqing

Latest Information Update: 19 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator St. Michaels Hospital; University of Toronto
  • Developer Innogen Pharmaceutical Technology; Yinnuo Pharmaceutical Technology
  • Class Antihyperglycaemics; Obesity therapies; Recombinant fusion proteins
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Type 2 diabetes mellitus
  • Phase II Non-alcoholic steatohepatitis; Obesity

Most Recent Events

  • 19 Sep 2025 Phase-II clinical trials in Non-alcoholic steatohepatitis (Monotherapy) (SC) prior to September 2025 (Innogen Pharmaceutical technology pipeline, September 2025)
  • 11 Aug 2025 Shanghai Yinnuo Pharmaceutical plans a phase II trial for Obesity (SC) in Australia in August 2025 (NCT07114419)
  • 31 Mar 2025 Shanghai Yinnuo Pharmaceutical Technology initiates enrolment in phase-II clinical trials in Obesity in China (SC) (NCT06921486)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top